[2008 National Cardiology Guidelines: Prioritization requires consideration to other factors than scientific studies alone].
Sahlgrenska Universitetssjukhuset, Göteborg.
Kristina
K
Eklund
Lars
L
Grip
Bo
B
Israelsson
Lars-Ake
LA
Levin
Bertil
B
Lindahl
Lars
L
Wallentin
D000924:Anticholesteremic Agents / Q000191:economics*; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000191:economics / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D019317:Evidence-Based Medicine; D006292:Health Priorities; D006538:Heptanoic Acids / Q000191:economics; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics; D017410:Practice Guidelines as Topic; D011758:Pyrroles / Q000191:economics; D019821:Simvastatin / Q000191:economics
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin